IDH3A and glioblastoma: Less than 10% of glioblastoma (GBM, isocitrate dehydrogenase [IDH]-wild-type) patients survive longer than 5 years and the average length of survival after diagnosis is a dismal 12 to 18 months [1,2,3,4].